絞り込み

17363

広告

福岡・大牟田の浸水4mに、防災科研解析…「線状降水帯」相次いで発生 (読売新聞)

防災科学技術研究所(茨城県つくば市)は6日夜、九州北部の大雨で、福岡県大牟田市では浸水の深さが少なくとも4メートルに達したとの解析結果を発表した。 防災科研は、...

  1. [企業] Dragonfly社が5500...
  2. コロナ 3か月以上闘病の米 俳優が死去
  3. 障害者雇用に関する優良な中小事業主に対す...
  4. 新型コロナウイルスに関連した患者等の発生...

ニュース一覧

Betrixaban for prevention of venous thromboembolism in acute medically ill patients.

著者 Beyer-Westendorf J , Verhamme P , Bauersachs R
Eur Heart J Suppl.2018 May ; 20(Suppl E):E16-E22.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (82view , 0users)

Full Text Sources

Miscellaneous

Venous thromboembolism (VTE) is a common, potentially preventable cause of morbidity and mortality among acute medically ill patients. More than half of VTE events in this population occur after hospital discharge. Thus, providing extended-duration VTE prophylaxis from in-hospital through the post-discharge continuum may improve the quality of care in patients at risk of VTE. Betrixaban is a new oral, once-daily factor Xa inhibitor approved by the United States (US) Food and Drug Administration (FDA) for extended-duration prophylaxis of VTE in acute medically ill patients. The clinical efficacy and safety of betrixaban in acute medically ill patients perceived to be at high risk for VTE were evaluated in a large, randomized, double-blind, active-controlled, multinational clinical trial [Acute Medically Ill VTE Prevention With Extended Duration Betrixaban (APEX)]. Patients were randomized to receive subcutaneous enoxaparin (10 ± 4 days) or oral betrixaban (35-42 days) plus matching placebos. The primary efficacy outcome was a composite of asymptomatic proximal deep vein thrombosis and symptomatic VTE; the primary safety measure was major bleeding. Extended-duration betrixaban reduced VTE events without an increase in major bleeding in the modified intent-to-treat analysis. analyses of the APEX trial provided further evidence to support the efficacy and safety of betrixaban in reducing all-cause ischaemic stroke, fatal or irreversible ischaemic or bleeding events, as well as reducing VTE-related rehospitalization. In summary, analyses of the APEX study demonstrated a positive benefit-risk profile for extended prophylaxis of VTE with betrixaban in acute medically ill patients. This is likely to have important public health and health economic implications.
PMID: 29977165 [PubMed]
印刷用ページを開く Endnote用テキストダウンロード